Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2020

01-10-2020 | Arterial Occlusive Disease | PRECLINICAL STUDIES

Combating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes

Authors: Hendawy OM, Mehrez E. El-Naggar, Mona El-Banna, Moustafa M. G. Fouda, Sarah I. Othman, Ahmed A. Allam, Osama M. Morsy

Published in: Investigational New Drugs | Issue 5/2020

Login to get access

Summary

Diabetes with poor glycemic control is accompanying with an increased risk of disease namely atherosclerotic cardiovascular. Diosmin (DSN), which is obtained from citrus fruit used to assist the treatment of hemorrhoids or chronic venous atherosclerosis diseases, has an antioxidant, anti-hyperglycemic and anti-inflammatory effect. DSN is characterized by poor water solubility which limits its absorption by the gastrointestinal tract. To overcome this limitation, this study was designed to increase DSN bioavailability and solubility, through its loading on polymeric matrix; hydroxypropyl starch (HPS) and Poly lactide–glycolide-chitin (PLGA/chitin) to prepare Diosmin nanoparticles (DSN-NPs). Two methods were used to prepare DSN- NPs; Emulsion–solvent evaporation and Acid–base neutralization followed by further assessment on diabetes induced atherosclerosis The study was conducted on 50 animals assigned into 5 groups with 10 animals in each group: Group I: Normal rats received only normal saline, Group II: Diabetic rats, Group III: diabetic rats received oral DSN, Group IV: diabetic rats received DSN loaded HPS, Group V: diabetic rats received DSN loaded PLGA/chitin. Levels of total cholesterol, triglycerides, HDL-cholesterol, insulin, MDA and NO. plasminogen activator inhibitor-1 PAI-1), Paraoxonase-1(PON1), transforming growth factor-β1 (TGF-β1), NF-ҡB and Ang II were estimated. Our study revealed that, there was statistically significant difference between DSN treated group compared with DSN loaded HPS treated group and DSN loaded PLGA/chitin. Furthermore, the results obtained clearly disclosed no statistically significant difference between DSN loaded PLGA/chitin and control group exhibited DSN loaded PLGA/chitin has the higher ability to counteract the atherosclerosis factors induced by diabetes in all rats.
Literature
1.
Bullon P, Newman HN (2000) Battino M (2014) obesity, diabetes mellitus, atherosclerosis and chronic periodontitis: a shared pathology via oxidative stress and mitochondrial dysfunction? Periodontol 64:139–153
2.
Lind M, Svensson A-M, Kosiborod M et al (2014) Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 371:1972–1982PubMed
3.
Al-Mashhadi RH, Bjørklund MM, Mortensen MB et al (2015) Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs. Diabetologia 58:1926–1936PubMed
4.
Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363–1379PubMed
5.
Katakami N (2017) Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. J Atheroscler Thromb:RV17014
6.
Carr ME (2001) Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 15:44–54PubMed
7.
Cines DB, Pollak ES, Buck CA et al (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527–3561PubMed
8.
VERMA S, ANDERSON TJ (2001) The ten most commonly asked questions about endothelial function in cardiology. Cardiol Rev 9:250–252PubMed
9.
Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Jama 287:2570–2581PubMed
10.
Schmidt AM, Stern D (2000) Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2:430–436PubMed
11.
Zhang L, Gu FX, Chan JM et al (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761–769PubMed
12.
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1–20PubMed
13.
Imam F, Al-Harbi NO, Al-Harbi MM et al (2015) Diosmin downregulates the expression of T cell receptors, pro-inflammatory cytokines and NF-κB activation against LPS-induced acute lung injury in mice. Pharmacol Res 102:1–11PubMed
14.
Feldo M, Woźniak M, Wójciak-Kosior M et al (2018) Influence of diosmin treatment on the level of oxidative stress markers in patients with chronic venous insufficiency. Oxid Med Cell Longev 2018
15.
Anwer MK (2014) Development of diosmin loaded eudragit s100 polymeric nanoparticles: an investigation of antioxidant effect. IJBPAS 3:2015–2026
16.
17.
Kohli R, Meininger CJ, Haynes TE et al (2004) Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced diabetic rats. J Nutr 134:600–608PubMed
18.
Arab HH, Salama SA, Omar HA et al (2015) Diosmin protects against ethanol-induced gastric injury in rats: novel anti-ulcer actions. PLoS One 10:e0122417PubMedPubMedCentral
19.
Mannaa F, Ahmed HH, Estefan SF et al (2005) Saccharomyces cerevisiae intervention for relieving flutamide-induced hepatotoxicity in male rats. Die Pharm Int J Pharm Sci 60:689–695
20.
JUDZEWITSCH RG, PFEIFER MA, BEST JD et al (1982) Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J Clin Endocrinol Metab 55:321–328PubMed
21.
Richmond W (1973) Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 19:1350–1356PubMed
22.
Fossati P, Prencipe L (1982) Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28:2077–2080PubMed
23.
Lopes-Virella MF, Stone P, Ellis S, Colwell JA (1977) Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 23:882–884PubMed
24.
Glatter TR (1984) Hyperlipidemia: What is ‘normal,‘who should be treated and how. Postgrad Med 76:49–59PubMed
25.
Ruiz-Larrea MB, Leal AM, Liza M et al (1994) Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids 59:383–388PubMed
26.
Ellman (1959) GL. Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77PubMed
27.
Hussein J, Refaat E, Morsy S et al (2013) Green tea attenuates experimental hepatitis in context of oxidative stress. J Appl Pharm Sci 3:124
28.
Mohamed NA, El-Naggar ME (2018) Amifostine-based nanoemulsion as promising protective agent for nephrotoxicity. J Innov Pharm Biol Sci 5:38–45
29.
30.
31.
32.
33.
34.
El-Feky GS, E-R MH, El-Sheikh MA et al (2015) Utilization of Crosslinked starch nanoparticles as a carrier for indomethacin and acyclovir drugs. Nanomedicine Nanotechnol 6:254
35.
Shaheen TI, El-Naggar ME, Hussein JS et al (2016) Antidiabetic assessment; in vivo study of gold and core-shell silver-gold nanoparticles on streptozotocin-induced diabetic rats. Biomed Pharmacother Biomed Pharmacother 83:865PubMed
36.
37.
38.
Al-Taweel A, Alqasoumi S, Alam P, Abdel-Kader M (2013) Densitometric-high-performance thin-layer chromatographic estimation of diosmin, hesperidin, and ascorbic acid in pharmaceutical formulations. JPC-Journal Planar Chromatogr TLC 26:336–342
39.
Xiao J, Kai G (2012) A review of dietary polyphenol-plasma protein interactions: characterization, influence on the bioactivity, and structure-affinity relationship. Crit Rev Food Sci Nutr 52:85–101PubMed
40.
Giannouli M, Karagkiozaki V, Pappa F et al (2018) Fabrication of quercetin-loaded PLGA nanoparticles via electrohydrodynamic atomization for cardiovascular disease. Mater Today Proc 5:15998–16005
41.
Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537–546PubMed
42.
Ritarwan K, Lelo A, Pane YS, Nerdy N (2018) Increasing atherosclerosis in Streptozotocin-induced diabetes into four groups of mice. Open access Maced J Med Sci 6:287PubMedPubMedCentral
43.
Srinivasan S, Pari L (2012) Ameliorative effect of diosmin, a citrus flavonoid against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats. Chem Biol Interact 195:43–51PubMed
44.
Husain K, Hernandez W, Ansari RA, Ferder L (2015) Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem 6:209PubMedPubMedCentral
45.
van Dijk DJ, Boner G, Giler S, Erman A (2001) Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat. J Renin-Angiotensin-Aldosterone Syst 2:193–198PubMed
46.
Ogata Y, Nemoto W, Nakagawasai O et al (2016) Involvement of spinal angiotensin II system in streptozotocin-induced diabetic neuropathic pain in mice. Mol Pharmacol 90:205–213PubMed
47.
Ali FEM, Azouz AA, Bakr AG et al (2018) Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: the role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway. Food Chem Toxicol 120:294–304PubMed
48.
Chapman MJ, Ginsberg HN, Amarenco P et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361PubMedPubMedCentral
49.
50.
Taskinen M-R (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749PubMed
51.
Queenthy SS, John B (2013) Diosmin exhibits anti-hyperlipidemic effects in isoproterenol induced myocardial infarcted rats. Eur J Pharmacol 718:213–218PubMed
52.
El-Fawal R, El Fayoumi HM, Mahmoud MF (2018) Diosmin and crocin alleviate nephropathy in metabolic syndrome rat model: effect on oxidative stress and low grade inflammation. Biomed Pharmacother 102:930–937PubMed
53.
Petersen KE, Lykkesfeldt J, Raun K, Rakipovski G (2017) Brief communication: plasma lipid oxidation predicts atherosclerotic status better than cholesterol in diabetic apolipoprotein E deficient mice. Exp Biol Med 242:88–91
54.
Yoon J-H, Kim J-Y, Park J-K, Ko S-B (2015) Oxidative damage markers are significantly associated with the carotid artery intima-media thickness after controlling for conventional risk factors of atherosclerosis in men. PLoS One 10:e0119731PubMedPubMedCentral
55.
Yang R-L, Shi Y-H, Hao G et al (2008) Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index. J Clin Biochem Nutr 43:154–158PubMedPubMedCentral
56.
Gupta S, Sharma SB, Singh UR, Bansal SK (2011) Salutary effect of Cassia auriculata L. leaves on hyperglycemia-induced atherosclerotic environment in streptozotocin rats. Cardiovasc Toxicol 11:308
57.
Gomathi P, Iyer AC, Murugan PS et al (2018) Association of paraoxonase-1 gene polymorphisms with insulin resistance in south Indian population. Gene 650:55–59PubMed
58.
Kunutsor SK, Kieneker LM, Bakker SJL et al (2017) Incident type 2 diabetes is associated with HDL, but not with its anti-oxidant constituent-paraoxonase-1: the prospective cohort PREVEND study. Metabolism 73:43–51PubMed
59.
Viktorinova A, Jurkovicova I, Fabryova L et al (2018) Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in type 2 diabetes. Diabetes Res Clin Pract 140:174–182PubMed
60.
Campanero MA, Escolar M, Perez G et al (2010) Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography–atmospheric pressure chemical ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 51:875–881PubMed
61.
Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792–1801PubMed
62.
Moustapha M, Chadhli-Chaieb M, Mahjoub T, Chaieb L (2017) Genetic and metabolic determinants of plasminogen activator inhibitor 1 (PAI-1) in Tunisian type 2 diabetes patients. Open J Endocr Metab Dis 7:141
63.
Mahmoud AM (2017) Exercise amaliorates metabolic disturbances and oxidative stress in diabetic cardiomyopathy: possible underlying mechanisms. In: Exercise for Cardiovascular Disease Prevention and Treatment. Springer, pp 207–230
64.
Gilmore TD (2006) Introduction to NF-κB: players, pathways, perspectives. Oncogene 25:6680PubMed
65.
Tedgui A, Mallat Z (2001) Anti-inflammatory mechanisms in the vascular wall. Circ Res 88:877–887PubMed
66.
Shrikhande GV, Scali ST, da Silva CG et al (2010) O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS One 5:e14240PubMedPubMedCentral
67.
Saad AS, Mohamed KAA (2017) Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome. Middle East Fertil Soc J 22:206–210
68.
Soufy H, Lin TS, Das S, Zakaria Z (2012) Histological changes in the heart and the proximal aorta in experimental diabetic rats fed with Piper sarmentsoum. African J Tradit Complement Altern Med 9:396–404
69.
Aronson D, Rayfield EJ (2002) How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 1:1PubMedPubMedCentral
Metadata
Title
Combating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes
Authors
Hendawy OM
Mehrez E. El-Naggar
Mona El-Banna
Moustafa M. G. Fouda
Sarah I. Othman
Ahmed A. Allam
Osama M. Morsy
Publication date
01-10-2020
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2020
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-020-00905-6

Other articles of this Issue 5/2020

Investigational New Drugs 5/2020 Go to the issue

PRECLINICAL STUDIES

Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology

PRECLINICAL STUDIES

Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models

PHASE I STUDIES

Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients

PRECLINICAL STUDIES

W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors

PHASE I STUDIES

A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

PHASE I STUDIES

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits